Dysregulation of signaling pathways and putative biomarkers in liver cancer stem cells (Review)

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 3-12

  Song, Kai ^a   Wu, Junhua ^a   Jiang, Chunping ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Cancer stem cell; Hepatocellular carcinoma; Liver cancer stem cell; Putative biomarker; Signaling pathway

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; SONIC HEDGEHOG PROTEIN; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; WNT PROTEIN;

CANCER STEM CELL; CARCINOGENESIS; CELL FUNCTION; DISEASE MARKER; HUMAN; LIVER CANCER; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84872845149     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2082     Document Type: Review

References (160)

1. Yu MC and Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127 (Suppl 1): S72-S78, 2004.
2. Bosch FX, Ribes J, Cleries R and Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211, 2005.
3. Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308, 2008.
4. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W and Taylor-Robinson SD: Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 3: 353-367, 2009.
5. Kumar M, Kumar R, Hissar SS, et al: Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol 22: 1104-1111, 2007.
6. Carr BI: Hepatocellular carcinoma: current management and future trends. Gastroenterology 127 (Suppl 1): S218-S224, 2004.
7. Kassahun WT, Fangmann J, Harms J, Hauss J and Bartels M: Liver resection and transplantation in the management of hepa¬tocellular carcinoma: a review. Exp Clin Transplant 4: 549-558, 2006.
8. Witjes CD, Verhoef C, Verheul HM and Eskens FA: Systemic treatment in hepatocellular carcinoma; 'A small step for man. . . '. Neth J Med 67: 86-90, 2009.
9. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
10. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hema¬topoietic cell. Nat Med 3: 730-737, 1997.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
12. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
13. Klarmann GJ, Hurt EM, Mathews LA, et al: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 26: 433-446, 2009.
14. Kim CF, Jackson EL, Woolfenden AE, et al: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835, 2005.
15. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008.
16. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
17. Chu P, Clanton DJ, Snipas TS, et al: Characterization of a subpopulation of colon cancer cells with stem cell-like prop¬erties. Int J Cancer 124: 1312-1321, 2009.
18. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.
19. Li C, Lee CJ and Simeone DM: Identification of human pancreatic cancer stem cells. Methods Mol Biol 568: 161-173, 2009.
20. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
21. Rahman R, Heath R and Grundy R: Cellular immortality in brain tumours: an integration of the cancer stem cell paradigm. Biochim Biophys Acta 1792: 280-288, 2009.
22. Sun YL, Yin SY, Xie HY, et al: Stem-like cells in hepatitis B virus-associated cirrhotic livers and adjacent tissue to hepato¬cellular carcinomas possess the capacity of tumorigenicity. J Gastroenterol Hepatol 23: 1280-1286, 2008.
23. Roskams TA, Theise ND, Balabaud C, et al: Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 39: 1739-1745, 2004.
24. Petersen BE, Bowen WC, Patrene KD, et al: Bone marrow as a potential source of hepatic oval cells. Science 284: 1168-1170, 1999.
25. Shi XL, Gu JY, Han B, Xu HY, Fang L and Ding YT: Magnetically labeled mesenchymal stem cells after autologous transplantation into acutely injured liver. World J Gastroenterol 16: 3674-3679, 2010.
26. Theise ND, Nimmakayalu M, Gardner R, et al: Liver from bone marrow in humans. Hepatology 32: 11-16, 2000.
27. Rowe PM: Chronic Lyme disease: the debate goes on. Lancet 355: 1436, 2000.
28. Bae SH, Choi JY, Yoon SK, et al: Thy1-positive bone marrow stem cells express liver-specific genes in vitro and can mature into hepatocytes in vivo. Hepatol Int 2: 63-71, 2008.
29. Gournay J, Auvigne I, Pichard V, Ligeza C, Bralet MP and Ferry N: In vivo cell lineage analysis during chemical hepato¬carcinogenesis in rats using retroviral-mediated gene transfer: evidence for dedifferentiation of mature hepatocytes. Lab Invest 82: 781-788, 2002.
30. Bralet MP, Pichard V and Ferry N: Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology 36: 623-630, 2002.
31. Dumble ML, Croager EJ, Yeoh GC and Quail EA: Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 23: 435-445, 2002.
32. Fujii T, Zen Y, Harada K, et al: Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma - human and cell culture study. Hum Pathol 39: 1185-1196, 2008.
33. Nomoto K, Tsuneyama K, Cheng C, et al: Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype. Pathol Res Pract 202: 71-76, 2006.
34. Tanaka S, Yamamoto T, Tanaka H, et al: Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: immunohistochemical evidence. Hepatol Res 32: 52-57, 2005.
35. Zhang F, Chen XP, Zhang W, et al: Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52: 224-232, 2008.
36. Komuta M, Spee B, Vander Borght S, et al: Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47: 1544-1556, 2008.
37. de Lima VM, Oliveira CP, Alves VA, et al: A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol 49: 1055-1061, 2008.
38. Grozdanov PN, Yovchev MI and Dabeva MD: The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest 86: 1272-1284, 2006.
39. Caja L, Ortiz C, Bertran E, et al: Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal 19: 683-694, 2007.
40. Herzer K, Grosse-Wilde A, Krammer PH, Galle PR and Kanzler S: Transforming growth factor-beta-mediated tumor necrosis factor-related apoptosis-inducing ligand expression and apoptosis in hepatoma cells requires functional cooperation between Smad proteins and activator protein-1. Mol Cancer Res 6: 1169-1177, 2008.
41. Wang CL, Wan YL, Liu YC and Huang ZQ: TGF-beta1/SMAD signaling pathway mediates p53-dependent apoptosis in hepatoma cell lines. Chin Med Sci J 21: 33-35, 2006.
42. Yang YA, Zhang GM, Feigenbaum L and Zhang YE: Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepa¬tocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9: 445-457, 2006.
43. Kiyono K, Suzuki HI, Matsuyama H, et al: Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhi¬bition in human hepatocellular carcinoma cells. Cancer Res 69: 8844-8852, 2009.
44. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S and Giannelli G: Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50: 1140-1151, 2009.
45. Mikula M, Proell V, Fischer AN and Mikulits W: Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 209: 560-567, 2006.
46. Bae HJ, Eun JW, Noh JH, et al: Down-regulation of transforming growth factor beta receptor type III in hepatocellular carcinoma is not directly associated with genetic alterations or loss of heterozygosity. Oncol Rep 22: 475-480, 2009.
47. Ji GZ, Wang XH, Miao L, et al: Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. World J Gastroenterol 12: 644-648, 2006.
48. Lin SJ, Chang C, Ng AK, Wang SH, Li JJ and Hu CP: Prevention of TGF-beta-induced apoptosis by interleukin-4 through Akt activation and p70S6K survival signaling pathways. Apoptosis 12: 1659-1670, 2007.
49. Millet C and Zhang YE: Roles of Smad3 in TGF-beta signaling during carcinogenesis. Crit Rev Eukaryot Gene Expr 17: 281-293, 2007.
50. Zhang S, Fei T, Zhang L, et al: Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol 27: 4488-4499, 2007.
51. Kitisin K, Ganesan N, Tang Y, et al: Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 26: 7103-7110, 2007.
52. Baek HJ, Lim SC, Kitisin K, et al: Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology 48: 1128-1137, 2008.
53. Carmona-Cuenca I, Roncero C, Sancho P, et al: Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol 49: 965-976, 2008.
54. Caja L, Sancho P, Bertran E, Iglesias-Serret D, Gil J and Fabregat I: Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res 69: 7595-7602, 2009.
55. Sheahan S, Bellamy CO, Dunbar DR, Harrison DJ and Prost S: Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest. BMC Cancer 7: 215, 2007.
56. Zulehner G, Mikula M, Schneller D, et al: Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol 176: 472-481, 2010.
57. Tang Y, Kitisin K, Jogunoori W, et al: Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA 105: 2445-2450, 2008.
58. Lin L, Amin R, Gallicano GI, et al: The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28: 961-972, 2009.
59. Bagnyukova TV, Tryndyak VP, Muskhelishvili L, Ross SA, Beland FA and Pogribny IP: Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats. Cell Cycle 7: 3202-3210, 2008.
60. Dajani R, Fraser E, Roe SM, et al: Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J 22: 494-501, 2003.
61. Ha NC, Tonozuka T, Stamos JL, Choi HJ and Weis WI: Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. Mol Cell 15: 511-521, 2004.
62. Tauriello DV, Jordens I, Kirchner K, et al: Wnt/ß-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled. Proc Natl Acad Sci USA 109: E812-E820, 2012.
63. Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
64. Yochum GS, Sherrick CM, Macpartlin M and Goodman RH: A beta-catenin/TCF-coordinated chromatin loop at MYC inte¬grates 5' and 3' Wnt responsive enhancers. Proc Natl Acad Sci USA 107: 145-150, 2010.
65. Staal FJ, Meeldijk J, Moerer P, et al: Wnt signaling is required for thymocyte development and activates Tcf-1 mediated tran¬scription. Eur J Immunol 31: 285-293, 2001.
66. Taniguchi H and Chiba T: Stem cells and cancer in the liver. Dis Markers 24: 223-229, 2008.
67. Takigawa Y and Brown AM: Wnt signaling in liver cancer. Curr Drug Targets 9: 1013-1024, 2008.
68. Wang M, Xue L, Cao Q, et al: Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma 56: 533-541, 2009.
69. Wei W, Chua MS, Grepper S and So SK: Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 8: 76, 2009.
70. Yuzugullu H, Benhaj K, Ozturk N, et al: Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 8: 90, 2009.
71. Toyama T, Lee HC, Koga H, Wands JR and Kim M: Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res 8: 254-265, 2010.
72. Yonemitsu Y, Imazeki F, Chiba T, et al: Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 40: 1304-1311, 2009.
73. Chiba T, Miyagi S, Saraya A, et al: The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 68: 7742-7749, 2008.
74. Chiba T, Suzuki E, Negishi M, et al: 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 130: 2557-2567, 2012.
75. Cheng AS, Lau SS, Chen Y, et al: EZH2-mediated concordant repression of Wnt antagonists promotes ß-catenin-dependent hepatocarcinogenesis. Cancer Res 71: 4028-4039, 2011.
76. Zaret KS: Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. Nat Rev Genet 9: 329-340, 2008.
77. Yamashita T, Budhu A, Forgues M and Wang XW: Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67: 10831-10839, 2007.
78. Yamashita T, Ji J, Budhu A, et al: EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012-1024, 2009.
79. Yin L, Velazquez OC and Liu ZJ: Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol 80: 690-701, 2010.
80. Sharma VM, Draheim KM and Kelliher MA: The Notch1/c-Myc pathway in T cell leukemia. Cell Cycle 6: 927-930, 2007.
81. Moserle L, Ghisi M, Amadori A and Indraccolo S: Side popu¬lation and cancer stem cells: therapeutic implications. Cancer Lett 288: 1-9, 2010.
82. Wu WK, Cho CH, Lee CW, et al: Dysregulation of cellular signaling in gastric cancer. Cancer Lett 295: 144-153, 2010.
83. Moellering RE, Cornejo M, Davis TN, et al: Direct inhibition of the NOTCH transcription factor complex. Nature 462: 182-188, 2009.
84. Arora PS and Ansari AZ: Chemical biology: A Notch above other inhibitors. Nature 462: 171-173, 2009.
85. Farnie G and Clarke RB: Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev 3: 169-175, 2007.
86. Stylianou S, Clarke RB and Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res 66: 1517-1525, 2006.
87. Zardawi SJ, Zardawi I, McNeil CM, et al: High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology 56: 286-296, 2010.
88. Mittal S, Subramanyam D, Dey D, Kumar RV and Rangarajan A: Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 8: 128, 2009.
89. Hirose H, Ishii H, Mimori K, et al: Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors. Oncol Rep 23: 35-43, 2010.
90. Korkaya H and Wicha MS: HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 15: 1845-1847, 2009.
91. Wang C, Qi R, Li N, et al: Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J Biol Chem 284: 16183-16190, 2009.
92. Gramantieri L, Giovannini C, Lanzi A, et al: Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int 27: 997-1007, 2007.
93. Sikandar SS, Pate KT, Anderson S, et al: NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 70: 1469-1478, 2010.
94. Harrison H, Farnie G, Howell SJ, et al: Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70: 709-718, 2010.
95. Zhen Y, Zhao S, Li Q, Li Y and Kawamoto K: Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett 292: 64-72, 2010.
96. Hambardzumyan D, Becher OJ and Holland EC: Cancer stem cells and survival pathways. Cell Cycle 7: 1371-1378, 2008.
97. Huang S, He J, Zhang X, et al: Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 27: 1334-1340, 2006.
98. Cheng WT, Xu K, Tian DY, Zhang ZG, Liu LJ and Chen Y: Role of Hedgehog signaling pathway in proliferation and invasiveness of hepatocellular carcinoma cells. Int J Oncol 34: 829-836, 2009.
99. Patil MA, Zhang J, Ho C, Cheung ST, Fan ST and Chen X: Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther 5: 111-117, 2006.
100. Fu X, Wang Q, Chen X, et al: Expression patterns and polymor¬phisms of PTCH in Chinese hepatocellular carcinoma patients. Exp Mol Pathol 84: 195-199, 2008.
101. Sicklick JK, Li YX, Jayaraman A, et al: Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 27: 748-757, 2006.
102. Katoh Y and Katoh M: Integrative genomic analyses on GLI2: mechanism of Hedgehog priming through basal GLI2 expression, and interaction map of stem cell signaling network with P53. Int J Oncol 33: 881-886, 2008.
103. He J, Sheng T, Stelter AA, et al: Suppressing Wnt signaling by the hedgehog pathway through sFRP-1. J Biol Chem 281: 35598-35602, 2006.
104. Liu YJ, Wang Q, Li W, et al: Rab23 is a potential biological target for treating hepatocellular carcinoma. World J Gastroenterol 13: 1010-1017, 2007.
105. Omenetti A and Diehl AM: The adventures of sonic hedgehog in development and repair. II. Sonic hedgehog and liver devel¬opment, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol 294: G595-G598, 2008.
106. Pereira Tde A, Witek RP, Syn WK, et al: Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. Lab Invest 90: 1690-1703, 2010.
107. Eichenmuller M, Gruner I, Hagl B, et al: Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 49: 482-490, 2009.
108. Suzuki A, Sekiya S, Onishi M, et al: Flow cytometric isolation and clonal identification of self-renewing bipotent hepatic progenitor cells in adult mouse liver. Hepatology 48: 1964-1978, 2008.
109. Rountree CB, Ding W, He L and Stiles B: Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells 27: 290-299, 2009.
110. Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450, 2007.
111. Ma S, Chan KW, Hu L, et al: Identification and character¬ization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556, 2007.
112. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T and Moriwaki H: Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820-824, 2006.
113. Kohga K, Tatsumi T, Takehara T, et al: Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 52: 872-879, 2010.
114. Yao J, Zhang T, Ren J, Yu M and Wu G: Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol Rep 22: 781-787, 2009.
115. Song W, Li H, Tao K, et al: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62: 1212-1218, 2008.
116. Ma S, Chan KW, Lee TK, et al: Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6: 1146-1153, 2008.
117. Zhu Z, Hao X, Yan M, et al: Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 126: 2067-2078, 2010.
118. You H, Ding W and Rountree CB: Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 51: 1635-1644, 2010.
119. Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758, 2008.
120. Ma S, Tang KH, Chan YP, et al: miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707, 2010.
121. Salnikov AV, Kusumawidjaja G, Rausch V, et al: Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 275: 185-193, 2009.
122. Schmelzer E and Reid LM: EpCAM expression in normal, non-pathological tissues. Front Biosci 13: 3096-3100, 2008.
123. Kimura O, Takahashi T, Ishii N, et al: Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci 101: 2145-2155, 2010.
124. Ji J, Yamashita T, Budhu A, et al: Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480, 2009.
125. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z and Feitelson MA: Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 71: 3701-3708, 2011.
126. Lu TY, Lu RM, Liao MY, et al: Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferen¬tiated phenotype of human embryonic stem cells. J Biol Chem 285: 8719-8732, 2010.
127. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996.
128. Ding XW, Wu JH and Jiang CP: ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86: 631-637, 2010.
129. Chiba T, Kita K, Zheng YW, et al: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44: 240-251, 2006.
130. Shi GM, Xu Y, Fan J, et al: Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise meta¬static potentials. J Cancer Res Clin Oncol 134: 1155-1163, 2008.
131. Zhang N, Li R, Tao KS, et al: Characterization of a stem-like population in hepatocellular carcinoma MHCC97 cells. Oncol Rep 23: 827-831, 2010.
132. Kamohara Y, Haraguchi N, Mimori K, et al: The search for cancer stem cells in hepatocellular carcinoma. Surgery 144: 119-124, 2008.
133. Qiang GH, Yu DC and Jiang CP: Side population cells and liver cancer stem cells. World Chin J Digestol 18: 971-974, 2010 (In Chinese).
134. Polgar O, Robey RW and Bates SE: ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4: 1-15, 2008.
135. Sarkadi B, Ozvegy-Laczka C, Nemet K and Varadi A: ABCG2 - a transporter for all seasons. FEBS Lett 567: 116-120, 2004.
136. Han B and Zhang JT: Multidrug resistance in cancer chemo¬therapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 4: 31-42, 2004.
137. Zen Y, Fujii T, Yoshikawa S, et al: Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 170: 1750-1762, 2007.
138. Xi Z, Jiang CP and Ding YT: Expression of stem cell marker ABCG2 and its significance in hepatocellular carcinoma tissue and cell lines. World Chin J Digestol 17: 247-252, 2009.
139. Hu C, Li H, Li J, et al: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29: 2289-2297, 2008.
140. Yang ZF, Ngai P, Ho DW, et al: Identification of local and circu¬lating cancer stem cells in human liver cancer. Hepatology 47: 919-928, 2008.
141. Yang ZF, Ho DW, Ng MN, et al: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13: 153-166, 2008.
142. Haraguchi N, Ishii H, Mimori K, et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120: 3326-3339, 2010.
143. Oliva J, French BA, Qing X and French SW: The identification of stem cells in human liver diseases and hepatocellular carcinoma. Exp Mol Pathol 88: 331-340, 2010.
144. Martinez-Chantar ML, Lu SC, Mato JM, et al: The role of stem cells/progenitor cells in liver carcinogenesis in glycine N-methyltransferase deficient mice. Exp Mol Pathol 88: 234-237, 2010.
145. Andersen JB, Loi R, Perra A, et al: Progenitor-derived hepato¬cellular carcinoma model in the rat. Hepatology 51: 1401-1409, 2010.
146. Kim H, Choi GH, Na DC, et al: Human hepatocellular carcinomas with 'stemness'-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 54: 1707-1717, 2011.
147. Yang W, Yan HX, Chen L, et al: Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68: 4287-4295, 2008.
148. Xie Z, Choong PF, Poon LF, et al: Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemo¬sensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 62: 949-957, 2008.
149. Yu F, Hao X, Zhao H, et al: Delta-like 1 contributes to cell growth by increasing the interferon-inducible protein 16 expression in hepatocellular carcinoma. Liver Int 30: 703-714, 2010.
150. Machida K, Tsukamoto H, Mkrtchyan H, et al: Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA 106: 1548-1553, 2009.
151. Knight B, Tirnitz-Parker JE and Olynyk JK: C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology 135: 969-979, 2008.
152. Okamura D, Ohtsuka M, Kimura F, et al: Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection. Mod Pathol 21: 847-855, 2008.
153. Jabari S, Meissnitzer M, Quint K, et al: Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo. Int J Oncol 35: 69-80, 2009.
154. Yu J, Vodyanik MA, Smuga-Otto K, et al: Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920, 2007.
155. Zhong X, Li N, Liang S, Huang Q, Coukos G and Zhang L: Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem 285: 41961-41971, 2010.
156. Viswanathan SR, Powers JT, Einhorn W, et al: Lin28 promotes transformation and is associated with advanced human malig¬nancies. Nat Genet 41: 843-848, 2009.
157. Yang X, Lin X, Zhong X, et al: Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 70: 9463-9472, 2010.
158. Smith LM, Nesterova A, Ryan MC, et al: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99: 100-109, 2008.
159. Wang L, Su W, Liu Z, et al: CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepato¬cellular carcinoma. Biomaterials 33: 5107-5114, 2012.
160. Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC and Wong J: Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg 254: 569-576, 2011.